

blood

2006 107: 2839-2845
Prepublished online December 20, 2005;
doi:10.1182/blood-2005-08-3325

Identifying a common molecular mechanism for inhibition of MITF and STAT3 by PIAS3

Carmit Levy, Yu-Nee Lee, Hovav Nechushtan, Ora Schueler-Furman, Amir Sonnenblick, Shelley Hacohen and Ehud Razin

Articles on similar topics can be found in the following Blood collections

[Immunobiology](#) (4423 articles)

[Signal Transduction](#) (1930 articles)

[Gene Expression](#) (1085 articles)

Information about reproducing this article in parts or in its entirety may be found online at:
http://bloodjournal.hematologylibrary.org/site/misc/rights.xhtml#repub_requests

Information about ordering reprints may be found online at:
<http://bloodjournal.hematologylibrary.org/site/misc/rights.xhtml#reprints>

Information about subscriptions and ASH membership may be found online at:
<http://bloodjournal.hematologylibrary.org/site/subscriptions/index.xhtml>

Blood (print ISSN 0006-4971, online ISSN 1528-0020), is published weekly by the American Society of Hematology, 2021 L St, NW, Suite 900, Washington DC 20036.

Copyright 2011 by The American Society of Hematology; all rights reserved.



Identifying a common molecular mechanism for inhibition of MITF and STAT3 by PIAS3

Carmit Levy, Yu-Nee Lee, Hovav Nechushtan, Ora Schueler-Furman, Amir Sonnenblick, Shelley Hacohen, and Ehud Razin

Protein inhibitor of activated STAT3 (PIAS3) functions in vivo as a key molecule in suppressing the transcriptional activity of both microphthalmia transcription factor (MITF) and signal transducer and activator of transcription 3 (STAT3), 2 transcription factors that play a major role in the regulation of growth and function in mast cells and melanocytes. Previously, we have demonstrated binding of PIAS3 to MITF leading to the inhibition of

MITF transcriptional activity. Following cellular activation, PIAS3 is released from MITF and binds to STAT3. Now we have localized a common binding motif in PIAS3 for MITF and STAT3. This motif (PIAS₈₂₋₁₃₂), which contains 50 amino acids, is sufficient for the inhibition of both MITF and STAT3. Three-dimensional protein modeling demonstrated that this motif contains 2 alpha helices. Disruption of one of the helices led to the loss of PIAS3

inhibitory activity. In addition to contributing to our understanding of the mechanisms of PIAS3 activity, these results could pave the way toward the formulation of an antioncogenic agent for the inhibition of both STAT3 and MITF. (Blood. 2006;107:2839-2845)

© 2006 by The American Society of Hematology

Introduction

Microphthalmia transcription factor (MITF) is a basic helix-loop-helix leucine zipper (bHLH-Zip) DNA-binding protein.¹ Its gene resides at the *mi* locus in mice,² and mutation of this gene results in deafness, bone loss, small eyes, and poorly pigmented eyes and skin.³ The primary cell types affected in MITF-deficient mice are mast cells, osteoclasts, and melanocytes.³ In humans, mutation in this gene causes Waardenburg syndrome type II.⁴ MITF regulates the expression of mouse mast-cell protease 6 (*mMCP-6*),⁵ *mMCP-5*,⁶ *c-kit*,⁷ *p75* nerve growth factor,⁶ granzyme B,⁸ tryptophan hydroxylase,⁹ and others. MITF has been described as a master regulatory gene for melanocytes¹⁰ and has been shown to play important roles in the regulation of *Bcl-2* and *CDK2*.¹¹

Recently, it has been demonstrated that MITF is amplified in a significant number of malignant melanomas and can act as an important lineage survival oncogene in these tumors.¹² It has been proposed that, similar to the androgen receptor, MITF is important both for differentiation of melanocytes and for tumor transformation.¹²

Signal transducer and activator of transcription 3 (STAT3) is a transcription factor involved in signal transduction pathways that are activated by several extracellular stimuli including the IL-6 family of cytokines. It is tyrosine phosphorylated by Janus kinase (JAK) and translocates as a dimer into the nucleus where it activates specific genes.¹³ STAT3 signaling has been shown to prevent programmed cell death and enhance cellular proliferation through the regulation of genes such as *Bcl-XL*, *Mcl-1*, *c-Myc*, and cyclin D1.¹⁴⁻¹⁷ Activated STAT3 is involved in the regulation of cell

growth, differentiation, and survival.¹⁸ In many cancers, overactivation of STAT3 has been identified and was described to have a pivotal role in cancer progression through direct effects on the tumor-cell proliferation.¹⁹

Protein inhibitor of activated STAT3 (PIAS3)²⁰ has been identified as an inhibitor of both activated STAT3²⁰ and MITF.^{21,22} In our previous work, we reported that the MITF-PIAS3-STAT3 network of interactions is set in motion when mast cells are activated by interleukin-6 (IL-6) or stem-cell factor (SCF). This leads to the phosphorylation and transcriptional activation of both MITF and STAT3 transcription factors.²³ Moreover, PIAS3 stimulates MITF sumoylation at 2 sumoylation sites, MITF K182 and K316.²⁴

The PIAS family of proteins contains several conserved domains: the SAP domain, which is required for repression of STAT1 by PIASy²⁵; the Miz-Zn finger/RING domain, which is essential for SUMO (small ubiquitin-like modifier) ligase activity²⁶; and the PINIT motif, which is required for nuclear retention of PIAS3.²⁷

In the present work, we identified a short stretch of 50 amino acids in the PINIT²⁷ domain of PIAS3 (PIAS₈₂₋₁₃₂) that can directly interact with MITF and STAT3. Transfection of constructs containing PIAS₈₂₋₁₃₂ resulted in down-regulation of MITF- and STAT3-dependent transcriptional activity. Furthermore, as a result of cross-species sequence analysis of PIAS3 and 3-dimensional peptide modeling, we identified an amino acid in this sequence, Y94, that is critical for PIAS3 binding to its target proteins. We

From the Department of Biochemistry, Hebrew University Hadassah Medical School, Jerusalem, Israel; the Department of Oncology, Hadassah Hebrew University Medical Center, Jerusalem, Israel; the Department of Biochemistry, University of Washington, Seattle, WA; and the Department of Molecular Genetics and Biotechnology, Hebrew University Hadassah Medical School, Jerusalem, Israel.

Submitted August 16, 2005; accepted November 22, 2005. Prepublished online as *Blood* First Edition Paper, December 20, 2005; DOI 10.1182/blood-2005-08-3325.

Supported by United States Binational Science Foundation (grant 2003009; E.R.), the Israeli Academy of Science (grant 144/04; E.R.), and the German-

Israeli Foundation for Scientific Research and Development (grant I-726-10.2/2002; E.R.).

C.L. and Y.-N.L. contributed equally to this work.

Reprints: Ehud Razin, Department of Biochemistry, Hebrew University Hadassah Medical School, POB 12272, Jerusalem 91120, Israel; e-mail: ehudr@cc.huji.ac.il.

The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.

© 2006 by The American Society of Hematology

explored the role played by this conserved Y94 in the structure of PIAS3 and in its function as an inhibitor of both MITF and STAT3.

Materials and methods

Cell culture and treatments

Melanoma BL6-B16 (ATCC no. CRL-6322; Manassas, VA) and RBL (ATCC no. CRL-2256) cells were cultured in a growth medium containing RPMI-1640 supplemented with 10% fetal calf serum, 2 mM L-glutamine, 2 mM nonessential amino acids, 100 U/mL penicillin, 100 µg/mL streptomycin (Gibco Invitrogen, Grand Island, NY), and 50 µM β-mercaptoethanol (Fisher Scientific, Medford, MA). NIH 3T3 (ATCC no. CRL-6361) cells were cultured and maintained in a growth medium containing DMEM, supplemented as for RPMI-1640. All the cells were grown in a humidified incubator at 37°C with 5% CO₂.

NIH 3T3 cells were stimulated with a chimeric molecule of IL-6/IL-6R kindly provided by Dr Michel Revel (Weizmann Institute, Rehovot, Israel).

Plasmid construction

Mouse *MITF* (1129 bp) was subcloned into the *Xba*I and *Hind*III sites of the pcDNA3.1 (–) vector (Gibco Invitrogen). Mouse *MITF* (1129 bp) was inserted into the pGEX-4T-3 vector (Stratagene, La Jolla, CA). The MITF responsive reporter plasmid pTRPM1²⁸ was generously provided by Dr David E. Fisher (Harvard Medical School, Boston, MA). The luciferase reporter plasmid pSP72,²⁹ containing the MITF binding region of the promoter and the first exon of the *mMCP-6* gene (–191 to +26), was generously provided by Y. Kitamura (Osaka, Japan).

pGEX2³⁰-mouse *STAT3* plasmid was kindly provided by Dr Dov Zipori (Weizmann Institute). pcDNA-STAT3 flag tagged and the M67 pTATA *Tk-Luc* reporter gene³¹ were kindly provided Dr James E. Darnell (The Rockefeller University, New York, NY).

The cDNA encoding the open reading frame of mouse *PIAS3* was subcloned into the *Xba*I and *Hind*III sites of the pcDNA3.1 (–) vector (Gibco Invitrogen). *PIAS3*₈₂₋₁₃₂ (150 bp) was subcloned into the *Xba*I and *Bam*HI sites of the pcDNA3.1 (–) vector (Gibco Invitrogen). Fidelity of all constructs was verified by direct sequencing.

Transient cotransfection and luciferase assay

NIH 3T3 cells (5 × 10⁵) were used in various luciferase assay experiments. NIH 3T3 cells were cotransfected with liposomes (Promega, San Luis Obispo, CA) with 0.1 µg luciferase reporter gene (of MITF or STAT3), 0.1 µg pcDNA-*MITF*, or 0.1 µg pcDNA-*PIAS3*, or with 0.1 µg pcDNA-*PIAS3*₈₂₋₁₃₂ (wild type or mutant), 0.1 µg pcDNA-STAT3, or 0.1 µg pcDNA (no insert was used as a nonspecific control). The cells were incubated in 24-well plates for 48 hours, treated or not with IL-6/IL-6R, lysed, and assayed for luciferase activity.

RBL cells (5 × 10⁶) were also used in luciferase assay experiments. Cells were transfected using nucleofector technology (solution R, program T-20; Amaxa Biosystems, Gaithersburg, MD). Cells were transfected with 5 µg luciferase reporter gene (MITF or STAT3), pcDNA (5 µg) with no insert was used as a nonspecific control. The cells were incubated in plates for 24 hours, lysed, and assayed for luciferase activity. All of the luciferase activity was normalized to the total protein concentration. The normalized value was then divided by the luciferase activity obtained by cotransfection of the reporter with pcDNA alone. The ratio was expressed as the relative luciferase activity.

Real-time quantitative polymerase chain reaction (PCR)

MITF and STAT3 responsive genes were measured by using real-time quantitative PCR. Total RNA was extracted from transfected melanoma BL6-B16 and RBL cell line. The cells were transfected with 0.1 µg pcDNA-*PIAS3*₁₋₆₂₈ or with 0.1 µg *PIAS3*₈₂₋₁₃₂, and mRNA levels of various genes were quantified by SYBR-green incorporation (SYBR Green PCR Master Mix; Applied Biosystems, Foster City, CA). SYBR-green incorporation to double-strand DNA permits the direct detection of PCR product after each amplification cycle (ABI Prism 7000 sequence detection system;

Applied Biosystems). The genes whose mRNA levels were quantified by real-time PCR are as follows: β-actin; STAT3 target genes: *CyclinD1* and *VEGF*; MITF target genes: *Tbx2*, *c-kit*, Granzyme B, and tryptophan hydroxylase; and the MITF and STAT3 target gene: *c-Fos*.

Primers

Bacteriophage T7 transcription regulatory element and ribosome binding site were fused with the *PIAS3* primers. The pcDNA3.1-mouse *PIAS3* was used as a template. Primers for the *PIAS3*₈₂₋₁₃₂ and *PIAS3*₄₄₃₋₅₈₅ were as follows: *PIAS3*₈₂₋₁₃₂: sense, 5'-CTAATACGACTCACTATAGGGAAGGAGATATACATATGGTCCACCATG and antisense, 5' TTACCTGGACGTGAGAATCTGCTGCAGCTGCTG; *PIAS3*₄₄₃₋₅₈₅: sense, 5' CTAATACGACTCACTATAGGGAAGGAGATATACATATGGGTCCACAGCCATCTTCGGTG and antisense, 5' TCAGTCCAAGGAAATGACGCTGACCG.

In vitro GST pull-down assay

MITF or STAT3 GST fusion proteins were expressed in protease-deficient *E coli* strain B12 and purified on glutathione-sepharose beads (Amersham Biosciences, Freiburg, Germany) essentially as described before.²¹ Pull-down assays³² were performed with GST-MITF or GST-STAT3 fusion protein (1 µg–5 µg) bound to sepharose beads and preincubated for 1 hour at 4°C in 1 mL binding buffer (PBS, 1 mM DTT, 1 mM EDTA, 5% glycerol, 0.1% NP40). ³⁵S-labeled *PIAS3*₁₋₆₂₈ (1–10 µL) or its fragments were synthesized using the TNT-coupled rabbit reticulocyte lysate system (Promega) and then added to each preincubation mix, and the binding reaction was carried out overnight at 4°C. Beads were washed 4 times in 1 mL PBS/290 mM NaCl and boiled for 7 minutes in sample buffer, and aliquots were examined by electrophoresis. Integrity and quantity of GST fusions were confirmed by Blue stain reagent (Pierce Biotechnology, Rockford, IL), and autoradiography detected the amount of retained full-length *PIAS3* and its fragments.

Computational structure prediction

Secondary structure prediction of both *PIAS3*₁₋₆₂₈ and *PIAS3*₈₂₋₁₃₂ was made using the PSIPRED server (<http://bioinf.cs.ucl.ac.uk/psipred/>³³). Models of the tertiary structure of *PIAS3*₈₂₋₁₃₂ were created by the de novo structure prediction method ROBETTA. Initial models were obtained from the ROBETTA server (<http://www.robetta.org>³⁴) and further refined by a standard full atom relax protocol.³⁵ The final models were selected from the inspection of the 10 lowest scoring and structurally distant models.

Multiple sequence alignments

Protein sequences were retrieved from GenBank,³⁶ and alignments were performed with ClustalW (EMBL, Heidelberg, Germany; <http://www.ebi.ac.uk/clustalw/>³⁷).

Results

Characterization of the 50-amino acid domain in PIAS3 that is associated with both MITF and STAT3

We have previously shown that *PIAS3* associated with both MITF and STAT3 through the same region, which is a major part of the PINIT domain. Using ClustalW software, we observed that a 50-amino acid motif of the N-terminus of *PIAS3* (*PIAS3*₈₂₋₁₃₂) is well conserved among *PIAS* family members (Figure 1).

In order to identify the minimal motif in PINIT that is responsible for the interaction with both MITF and STAT3, PCR fragments coding for 2 domains of *PIAS3* were constructed (Figure 2A), *PIAS3*₈₂₋₁₃₂ and *PIAS3*₄₄₃₋₅₈₅. MITF and STAT3 were expressed in bacteria as glutathione S-transferase (GST) fusion proteins, immobilized on glutathione-sepharose beads, and assayed

```

Mus - PIAS3 AF034080      LPFYEVYGELIRPTTLASTSSQRFEEAHFTFALTPQQVQQLTSS
Homo - PIAS3 BC030556    LPFYEVYGELIRPTTLASTSSQRFEEAHFTFALTPQQVQQLTSS
Rat - PIAS3 NM 031784    LPFYEVYGELIRPTTLASTSSQRFEEAHFTFALTPQQVQQLTSS
Homo - PIAS1 NM 016166    LPFYDLDLDELKPTSLASDSSQRFRETCFALTPQQVQQLSSS
Mus - PIAS1 BC051417     LPFYDLDLDELKPTSLASDSSQRFRETCFALTPQQVQQLSSS
Homo - PIASy AF077952    LFFFNMLDELKPTLVPQNSQRFRETCFALTPQQVQQLIRKF
Mus - PIAS4 NM 021501    LFFFNMLDELKPTLVPQSAEKLQESPCIFALTPRQVEMIRNS
Mus - PIAS AF109174     LFFFNMLDELKPTLVPQSAEKLQESPCIFALTPRQVEMIRNS
*::** * . . . . . : *****: . . . . .

```

Figure 1. Alignment of PIAS family members. Fifty amino acids of the PIAS proteins (with their indicated GenBank accession numbers) have been aligned using ClustalW software. Mus indicates *Mus musculus*; Rat, *Rattus norvegicus*; and Homo, *Homo sapiens*. Arrows point to the 3 amino acids that were mutated.

for their ability to retain the in vitro–translated PIAS3 domains labeled with [³⁵S]methionine.

The results clearly show that PIAS3₈₂₋₁₃₂ is responsible for the association with both MITF and STAT3 (Figure 2B). Both PIAS3₈₂₋₁₃₂ and full-length PIAS3 (PIAS3₁₋₆₂₈) were associated only with GST-MITF or GST-STAT3, but not with the control GST (Figure 2B) or with PIAS3₄₄₃₋₅₈₅ (data not shown). The unlabeled PIAS3₈₂₋₁₃₂ and PIAS3₄₄₃₋₅₈₅ that were synthesized in vitro with similar efficiency (data not shown) were used as competitors for PIAS3₁₋₆₂₈ that was labeled with [³⁵S]methionine (Figure 2C). These results clearly show that PIAS3₈₂₋₁₃₂ associated strongly and specifically with both MITF and STAT3 in contrast to PIAS3₄₄₃₋₅₈₅, and thus that MITF and STAT3 interact specifically with the same domain (PIAS3₈₂₋₁₃₂) in PIAS3.

Effect of PIAS3₈₂₋₁₃₂ on MITF and STAT3 transcriptional activity

To examine the effect of PIAS3₈₂₋₁₃₂ on the transcriptional activity of MITF, we used the transient cotransfection assay. The luciferase reporter plasmid containing the mMCP-6 (MITF target gene) promoter was used. The luciferase reporter construct was cotransfected into 3T3-NIH (mouse embryo fibroblast) cells with an expression plasmid (pcDNA) containing MITF, and with expression plasmids containing PIAS3₁₋₆₂₈, PIAS3₈₂₋₁₃₂, or no insert (control). The expression of PIAS3₈₂₋₁₃₂ resulted in about 73%




Figure 2. A domain of 50 amino acids in PIAS3 (PIAS3₈₂₋₁₃₂) is associated with both MITF and STAT3. (A) Schematic representation of the full-length mouse PIAS3 (PIAS3₁₋₆₂₈), including the SAP domain, PINIT motif, the zinc finger motifs, and the 2 domains of PIAS3 investigated in this work. (B) Fragments PIAS3₈₂₋₁₃₂ and full-length PIAS3 (PIAS3₁₋₆₂₈) labeled with [³⁵S]methionine in vitro were added to GST-MITF or GST-STAT3 that was immobilized on glutathione-sepharose beads. Retained [³⁵S]-labeled PIAS3₁₋₆₂₈ or PIAS3₈₂₋₁₃₂ was determined by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and autoradiography. Input and GST alone are shown as control. One representative of 3 experiments is shown. (C) PIAS3₁₋₆₂₈ labeled with [³⁵S]methionine in vitro was added to GST-MITF or GST-STAT3 that was immobilized on glutathione-sepharose beads. Increasing concentrations of in vitro–translated unlabeled PIAS3₈₂₋₁₃₂ or PIAS3₄₄₃₋₅₈₅ was added to the mixtures. Retained [³⁵S]-labeled PIAS3₁₋₆₂₈ was determined by SDS-PAGE and autoradiography. One representative of 3 experiments is shown.




Figure 3. The inhibitory effect of PIAS3₈₂₋₁₃₂ on MITF and STAT3 transcriptional activity. (A) NIH-3T3 cells were cotransfected with an expression plasmid containing MITF, with a MITF luciferase reporter gene containing the mMCP-6 promoter, and with an expression plasmid containing either PIAS3₁₋₆₂₈ or PIAS3₈₂₋₁₃₂. Mean \pm SE of 4 experiments is shown. (B) NIH-3T3 cells were cotransfected with the STAT3 luciferase reporter gene (M67), with an expression plasmid containing STAT3, and with expression plasmids containing either PIAS3₁₋₆₂₈ or PIAS3₈₂₋₁₃₂. Cells were then treated with IL-6/IL-6R for 6 hours, with untreated cells as the control. One representative of 3 experiments is shown. (C) RBL cells were nuclear transfected with the STAT3 luciferase reporter gene (M67), and with expression plasmids containing either PIAS3₁₋₆₂₈ or PIAS3₈₂₋₁₃₂. Mean \pm SE of 4 experiments is shown. In all cases, luciferase activity of lysed cells was measured and normalized against protein concentration. For each transfection, the total DNA concentration was kept constant by complementing with the empty vector pcDNA.

inhibition of MITF transcriptional activity (Figure 3A), compared with about 88% inhibition seen with PIAS3₁₋₆₂₈.

In a complementary set of experiments, we examined the effect of the PIAS3₈₂₋₁₃₂ on the transcriptional activity of STAT3. The STAT3 reporter gene (M67) was cotransfected in 3T3-NIH cells with an expression plasmid containing STAT3, and with expression plasmids containing PIAS3₁₋₆₂₈, PIAS3₈₂₋₁₃₂, or no insert. After incubation of 48 hours, the cotransfected cells were treated for 6 hours with IL-6/IL-6R, a known STAT3 activator,³⁸ and then luciferase activity was measured. As shown in Figure 3B, IL-6/IL-6 receptor (IL-6/IL-6R) induced STAT3 luciferase activity, whereas the expression of PIAS3₁₋₆₂₈ or PIAS3₈₂₋₁₃₂ resulted in a substantial reduction of the luciferase activity. In addition, rat basophilic leukemia (RBL) cells were nuclear transfected with STAT3 reporter gene (M67) and expression plasmid containing PIAS3₁₋₆₂₈, PIAS3₈₂₋₁₃₂, or no insert. Similar reductions in luciferase activity were obtained in these cells when transfected with PIAS3₁₋₆₂₈ and PIAS3₈₂₋₁₃₂ (Figure 3C).

These results indicate the ability of PIAS3₈₂₋₁₃₂ to inhibit the transcriptional activity of both MITF and STAT3 in transiently transfected cell lines.

The effect of PIAS3₈₂₋₁₃₂ on STAT3- and MITF-mediated gene expression

The inhibitory effect of PIAS3₈₂₋₁₃₂ on the endogenous transcriptional activity of MITF and STAT3 in melanocytes and mast cells




Figure 4. The effect of PIAS3⁸²⁻¹³² on STAT3- and MITF-mediated gene expression. (A) Quantitative real-time PCR analysis of MITF target genes (*c-Kit* and *Tbx2*), STAT3 target genes (*CyclinD1* and *VEGF*), and MITF and STAT3 target gene (*c-fos*) from transfected melanocytes. (B) Quantitative RT-PCR analysis of MITF mast cell target genes (*GrB* and *TRP*) from transfected mast cells. In both cases, cells were transfected with expression plasmids containing PIAS3¹⁻⁶²⁸, PIAS3⁸²⁻¹³², or an empty vector. Total RNA (1.7 μ g) was used from each transfection experiment. Transcript levels of MITF and STAT3 target genes were normalized to actin and performed in triplicate.

was assessed using B16 (mouse melanoma cell line) or RBL cells, respectively, transfected with expression plasmids containing either PIAS3¹⁻⁶²⁸ or PIAS3⁸²⁻¹³². Quantitative real-time PCR was performed on the RNA samples for the following genes: (1) MITF target genes: *c-kit*,⁷ T-box transcription factor 2 (*Tbx2*),^{17,39} Granzyme B⁸ (*GrB*), and tryptophan hydroxylase⁴⁰ (*TRP*); (2) STAT3 target genes: CyclinD1²⁶ and vascular endothelial growth factor (*VEGF*)⁴¹; (3) MITF and STAT3 target gene: *c-fos*.⁴²

The real-time PCR analysis on the melanoma cells clearly shows that the transcript levels of MITF target genes such as *c-kit* and *Tbx2* and of STAT3 target genes such as CyclinD1 and *VEGF* were significantly suppressed when cells were transfected with the expression plasmid containing PIAS3⁸²⁻¹³² (Figure 4A). No such suppression of transcript levels of MITF and STAT3 target genes in these cells was observed with the empty vector only (pcDNA).

Recently, it was demonstrated by promoter analysis and chromatin immunoprecipitation assay that both STAT3 and MITF cooperatively up-regulate the expression of *c-fos*.⁴² In accordance with this observation, we demonstrate here that *c-fos* expression is also suppressed in melanocytes transfected with expression vector containing PIAS3⁸²⁻¹³² (Figure 4A).

The transcript levels of MITF target genes such as *GrB* and *TRP* in mast cells were measured by real-time PCR analysis on transfected RBL cells. Both the expression of PIAS3⁸²⁻¹³² and of PIAS3¹⁻⁶²⁸ in RBL cells caused a decrease in the transcript levels of MITF target genes (Figure 4B).

Secondary structure prediction of PIAS3⁸²⁻¹³²

The function of PIAS3⁸²⁻¹³² was further evaluated based on computational structure prediction. Secondary structure prediction programs such as PSIPRED³³ suggested several segments of secondary structure for PIAS3¹⁻⁶²⁸ and PIAS3⁸²⁻¹³², of which the most confident predictions include a short N-terminal helix (positions F90-L97) and a C-terminal helix (positions P122-L129) (Figure 5). An additional strand in the central region (positions F116-L120) was predicted with less confidence, due to the absence of a pairing strand and low hairpin probability.⁴³

The importance of Y94 at the N-terminal helix of PIAS3⁸²⁻¹³² for binding

In order to assess the importance of the N- and C-terminal-predicted helices to the structure and binding function of PIAS3⁸²⁻¹³², we mutated residues in those helices to proline, a helix breaker.⁴⁴ The importance of the N-terminal helix was assessed by the Y94P mutation, while the C-terminal helix was assessed by a double mutation of L125P and Q126P. Secondary structure prediction for the mutants indicates that the helices will be significantly shortened—and thus probably removed (Figure 5). In addition, sequence alignment of PIAS sequences showed that Y94 is conserved in the subset of PIAS3 family members (Figure 1, arrows), suggesting a possible functional role of this residue.




Figure 5. Predicted effects of the Y94P and L125P, Q126P mutations on the secondary structure of the PIAS3⁸²⁻¹³² segment. The secondary structure was predicted with PSIPRED. Confidence values (ranging from 0-9; 9 indicates highest confidence) are shown in bars along the PIAS3 sequence for the PIAS3¹⁻⁶²⁸ protein (▨), the segment PIAS3⁸²⁻¹³² (■), and the mutants PIAS3^{82-132; Y94P} (□) and PIAS3^{82-132; L125P, Q126P} (▨). Predicted α helices and β strands are shown below the graph as tubes and arrows, respectively. Predictions are similar for PIAS3¹⁻⁶²⁸ and PIAS3⁸²⁻¹³², except for more confident location of a central β strand in the full sequence secondary structure prediction. Mutation(s) to proline reduce the confidence level of the helix prediction, both for the N- and C-terminal helix. This effect is somewhat more expressed at the N-terminus due to its initially weaker helical signal. This figure indicates that the N-terminal helix might be abolished by the Y94P mutation, while the C-terminal helix is significantly shortened by the L125P, Q126P double mutation.




Figure 6. The PIAS3₈₂₋₁₃₂; Y94P mutation has lost its ability both to interact with MITF and STAT3 and to inhibit their transcriptional activity. (A) In vitro-translated and [³⁵S]-labeled PIAS3₈₂₋₁₃₂, PIAS3₈₂₋₁₃₂; Y94P, and PIAS3₈₂₋₁₃₂; Q125P, L126P were incubated with GST-MITF, GST-STAT3, or GST immobilized on glutathione-sepharose beads. Retained [³⁵S]-labeled PIAS3₈₂₋₁₃₂, PIAS3₈₂₋₁₃₂; Y94P, and PIAS3₈₂₋₁₃₂; Q125P, L126P were determined by SDS-PAGE and autoradiography. One representative of 3 experiments is shown. (B) Luciferase reporter plasmids, containing a MITF promoter region of the mMCP-6, or a STAT3 reporter gene, M67, were cotransfected into NIH-3T3 cells, with expression plasmids containing PIAS3₁₋₆₂₈, PIAS3₈₂₋₁₃₂, PIAS3₈₂₋₁₃₂; Y94P, or PIAS3₈₂₋₁₃₂; Q125P, L126P. Luciferase activity of lysed cells was measured and normalized against protein concentration. For each transfection, the total DNA concentration was constant by complementing with the empty vector pcDNA. The mean ± SE of 4 experiments is shown. (C) Quantitative RT-PCR analysis of MITF target gene (*TRP*) from transfected RBL cells. Cells were nuclear transfected with expression plasmids containing PIAS3₁₋₆₂₈, PIAS3₈₂₋₁₃₂, PIAS3₈₂₋₁₃₂; Y94P, PIAS3₈₂₋₁₃₂; Q126P, L125P, or no insert. Transcript levels were normalized to actin and performed in triplicates. One representative of 3 experiments is shown.

MITF and STAT3 were expressed in bacteria as GST fusion proteins, immobilized on glutathione-sepharose beads, and assayed for their ability to retain the in vitro-translated PIAS3₈₂₋₁₃₂ or its mutants (PIAS3₈₂₋₁₃₂; Y94P, PIAS3₈₂₋₁₃₂; L125P, Q126P) labeled with [³⁵S]methionine. The results clearly show that the Y94P mutation abolished the ability of PIAS3 to associate with either MITF or STAT3, either due to disruption of the N-terminal helix by the mutation to proline or to the direct involvement of Y94 in binding (Figure 6A).

We then determined the effect of PIAS3₈₂₋₁₃₂ and its mutants on MITF or STAT3 transcriptional activity. NIH 3T3 fibroblasts were cotransfected either with an MITF reporter gene (mMCP-6) or with a STAT3 reporter gene (M67), and expression plasmids containing MITF, STAT3, PIAS3₁₋₆₂₈, PIAS3₈₂₋₁₃₂, PIAS3₈₂₋₁₃₂; Y94P, PIAS3₈₂₋₁₃₂; L125P, Q126P, or no insert. Almost no inhibitory effect was observed when cells were transfected with the PIAS3₈₂₋₁₃₂; Y94P mutant (Figure 6B). In contrast, the PIAS3₈₂₋₁₃₂; L125P, Q126P mutant caused about 50% inhibition of both MITF and STAT3 transcriptional activity. In the same experiment, PIAS3₁₋₆₂₈ and PIAS3₈₂₋₁₃₂ wild type showed about 60% inhibition of both MITF and STAT3 transcriptional activity (Figure 6B).

The inhibitory effect of different mutations of PIAS3₈₂₋₁₃₂ on the endogenous transcriptional activity of MITF in mast cells was assessed using RBL cells transfected with expression plasmid containing PIAS3₁₋₆₂₈, PIAS3₈₂₋₁₃₂, PIAS3₈₂₋₁₃₂; Y94P, PIAS3₈₂₋₁₃₂; L125P, Q126P, or no insert. Quantitative real-time PCR was performed to analyze the transcript level of the MITF target gene *TRP*.⁴⁰ Real-time PCR analysis clearly shows a significantly suppressed expression of the MITF target gene upon transfection with the expression plasmid containing PIAS3₈₂₋₁₃₂; L125P, Q126P (Figure 6C). No such suppression was observed for the MITF target gene in cells transfected with the expression plasmid containing either PIAS3₈₂₋₁₃₂; Y94P or empty vector (pcDNA).

These experimental results indicate that the N-terminal helix is responsible for the binding of PIAS3 to STAT3 and MITF, while shortening the C-terminal helix does not abolish these interactions. Furthermore, these data indicate that Y94 of the N-terminal helix plays a critical role in this interaction and in suppression of MITF and STAT3 transcriptional activity.

Discussion

PIAS3 is a regulator protein of several key transcription factors, including NFκB,⁴⁵ estrogen receptor,⁴⁶ STAT3,²⁰ and MITF.²³ Several functions have been described for this protein—as an E3 SUMO ligase,⁴⁶ as a transcriptional coactivator/repressor,⁴⁵ and as an inhibitor of the binding of the transcription factor to DNA.²³ The mechanisms involved in the binding of PIAS3 to its target and the modulation of their transcription have just begun to be explored. For example, it was found that the N-terminal part of PIAS3 is sufficient for binding to NFκB and that the transcriptional inactivation of this factor depends on a short sequence in the N-terminus of PIAS3.⁴⁵ Others have found that the protein domain PINIT allows nuclear translocation of PIAS3.²⁷

In the current study, we defined the specific sequence that allows PIAS3 to bind to 2 different transcription factors—STAT3 and MITF. Using the GST pull-down assay, we defined a short domain of PIAS3 (PIAS3₈₂₋₁₃₂), which can bind both to MITF and STAT3. These 50 amino acids are required for binding and inhibition of both MITF and STAT3 transcriptional activity in melanocytes and mast cells (Figures 3-4). To verify the potential inhibition activity of the PIAS3₈₂₋₁₃₂ peptide on the endogenous transcriptional activities of MITF and STAT3, we used real-time PCR to demonstrate that introduction and expression of this peptide into mast cells or melanocytes inhibits the expression of some of the known target genes of these transcription factors (Figure 4).

It has previously been described that PIAS3, but not PIAS1, promotes sumoylation of MITF.⁴⁷ Since this short amino acid sequence does not contain the sumoylation domain of PIAS3 and also does not contain the short sequence important for NFκB inactivation,⁴⁵ our current findings imply that PIAS3 can inhibit both MITF and STAT3 by a mechanism independent of sumoylation and of NFκB inactivation. Furthermore, whether PIAS3 works in vivo under most circumstances mainly as a sumo ligase modulating the gene-specific transcriptional activity of MITF, or via stoichiometric binding and inhibition of MITF transcriptional activity, is not clear at this point. It seems that PIAS3 behaves in a similar way to an enzyme, so that lower levels of PIAS3 compared

with MITF might still be sufficient to allow the sumoylation of many MITF molecules. Thus the mode of action of PIAS3 as a transcriptional repressor might depend on the specific stoichiometric relationship between itself and its target proteins in the cell at a specific time point.

As described in "Introduction," overactivation of both MITF and STAT3 has an important pro-oncogenic role in certain cancers.^{12,19} These observations provide substantial support to the notion that PIAS3₈₂₋₁₃₂ contains amino acids that are essential for the inhibitory activity of PIAS3 on MITF and STAT3. Small peptides constructed on the basis of PIAS3₈₂₋₁₃₂ could be the starting point for the formulation of potent inhibitors for both of these transcription factors. Such an approach might prove to be especially effective for tumors such as melanoma where both MITF and STAT3 transcription factors play an important role in tumor development and growth.

Using computational models of the secondary and tertiary structure of PIAS3₈₂₋₁₃₂, we predicted that this region contains 2 peptide helices. Cross-species analysis showed that Y94 is conserved in PIAS3 sequences only, suggesting its involvement in PIAS3-specific interactions to STAT3 and MITF. When we replaced this tyrosine with proline, a helix breaker, PIAS3 lost its ability to bind and inhibit MITF and STAT3 activity both in vitro and in vivo (Figure 6). The loss of binding could be due either to the disruption of the N-terminal helix or to the elimination of important contributions of the tyrosine side chain at the interface of PIAS3-STAT3 and PIAS3-MITF complexes. In order to evaluate these possibilities further, models of the tertiary structure of PIAS3₈₂₋₁₃₂ were created with the de novo structure prediction protocol of ROBETTA.^{34,35} The models were clustered based on structural similarity, and lowest energy models of large clusters were further inspected for the location and importance of the N- and C-terminal helices for the protein fold, with specific emphasis on potential contributions of Y94.

Figure 7A shows the lowest energy model encountered in this prediction, containing a tightly packed core. According to this model, either the relatively exposed Y94 side chain itself or the N-terminal helix in general could contribute directly to binding. Figure 7B shows a low-energy model taken from a largely populated cluster (large clusters indicate that a particular solution is found frequently, increasing the confidence in a correct prediction). Here, Y94 points more into the protein center, suggesting possible




Figure 7. Possible structures for the PIAS3₈₂₋₁₃₂ segment created by ROBETTA de novo modeling. Three representative models are shown: (A) the lowest energy model of the prediction runs; (B) low-energy model of largest cluster that contains lowest energy models; and (C) a model that includes a beta hairpin. The predicted elements of secondary structure (according to PSIPRED, Figure 5) are colored in red (helix) and yellow (strand). The positions that were mutated to proline (eg, Y94, L125, and Q126) are shown in sticks. Y94 points mostly into the core but is also accessible to interactions with protein partners. In contrast, Q126 is mostly exposed.

contributions to protein stability in addition to binding. Finally, Figure 7C shows another low-energy model from a highly populated cluster, including a beta hairpin to satisfy the hydrogen bond pairing in beta sheets. In this model, Y94 points into the protein center, and L125 and Q126 are in a distinct region of the protein, suggesting a structural role for Y94. These models imply the importance of Y94 in stability of the protein structure. In all models, the importance of the N-terminal helix to binding and stability cannot be precisely defined, and additional experiments are needed to evaluate the precise role of this helix in general, and of Y94 specifically.

To summarize, our results demonstrate that a short amino acid sequence from the N-terminus of PIAS3, PIAS3₈₂₋₁₃₂, is able to bind and inhibit the transcription factors MITF and STAT3. Furthermore, replacement of Y94 by proline leads to loss of the transcriptional repression of STAT3 and MITF by PIAS3. These results shed new light on possible regulatory mechanisms of PIAS3 activity on the pro-oncogenic transcription factors MITF and STAT3. In addition, these findings open unique experimental approaches for the formulation of effective inhibitors based on the interaction between PIAS3 and these transcription factors.

Acknowledgment

We thank Dr G. Kay for article preparation.

References

- Hodgkinson CA, Moore KJ, Nakayama A, et al. Mutations at the mouse microphthalmia locus are associated with defects in a gene encoding a novel basic-helix-loop-helix-zipper protein. *Cell*. 1993;74:395-404.
- Hughes MJ, Lingrel JB, Krakowsky JM, Anderson KP. A helix-loop-helix transcription factor-like gene is located at the mi locus. *J Biol Chem*. 1993;268:20687-20690.
- Moore KJ. Insight into the microphthalmia gene. *Trends Genet*. 1995;11:442-450.
- Tachibana M, Takeda K, Nobukuni Y, et al. Ectopic expression of MITF, a gene for Waardenburg syndrome type 2, converts fibroblasts to cells with melanocyte characteristics. *Nat Genet*. 1996;14:50-54.
- Morii E, Tsujimura T, Jippo T, et al. Regulation of mouse mast cell protease 6 gene expression by transcription factor encoded by the mi locus. *Blood*. 1996;88:2488-2494.
- Morii E, Jippo T, Hashimoto K, et al. Abnormal expression of mouse mast cell protease 5 gene in cultured mast cells derived from mutant mi/mi mice. *Blood*. 1997;90:3057-3066.
- Isozaki K, Tsujimura T, Nomura S, et al. Cell type-specific deficiency of c-kit gene expression in mutant mice of mi/mi genotype. *Am J Pathol*. 1994;145:827-836.
- Gommerman JL, Berger SA. Protection from apoptosis by steel factor but not interleukin-3 is reversed through blockade of calcium influx. *Blood*. 1998;91:1891-1900.
- Ito A, Morii E, Kim DK, et al. Inhibitory effect of the transcription factor encoded by the mi mutant allele in cultured mast cells of mice. *Blood*. 1999;93:1189-1196.
- Carreira S, Goodall J, Aksan I, et al. Mitf cooperates with Rb1 and activates p21Cip1 expression to regulate cell cycle progression. *Nature*. 2005;433:764-769.
- Du J, Widlund HR, Horstmann MA, et al. Critical role of CDK2 for melanoma growth linked to its melanocyte-specific transcriptional regulation by MITF. *Cancer Cell*. 2004;6:565-576.
- Garraway LA, Widlund HR, Rubin MA, et al. Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. *Nature*. 2005;436:117-122.
- Darnell JE Jr, Kerr IM, Stark GR. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. *Science*. 1994;264:1415-1421.
- Bowman T, Broome MA, Sinibaldi D, et al. Stat3-mediated Myc expression is required for Src transformation and PDGF-induced mitogenesis. *Proc Natl Acad Sci U S A*. 2001;98:7319-7324.
- Bromberg JF, Wrzeszczynska MH, Devgan G, et al. Stat3 as an oncogene. *Cell*. 1999;98:295-303.
- Grandis JR, Drenning SD, Zeng Q, et al. Constitutive activation of Stat3 signaling abrogates apoptosis in squamous cell carcinogenesis in vivo. *Proc Natl Acad Sci U S A*. 2000;97:4227-4232.
- Sinibaldi D, Wharton W, Turkson J, Bowman T, Pledger WJ, Jove R. Induction of p21WAF1/CIP1 and cyclin D1 expression by the Src oncoprotein in mouse fibroblasts: role of activated STAT3 signaling. *Oncogene*. 2000;19:5419-5427.
- Hirano T, Ishihara K, Hibi M. Roles of STAT3 in

- mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptors. *Oncogene*. 2000;19:2548-2556.
19. Inghirami G, Chiarle R, Simmons WJ, Piva R, Schlessinger K, Levy DE. New and old functions of STAT3: a pivotal target for individualized treatment of cancer. *Cell Cycle*. 2005;4:1131-1133.
 20. Chung CD, Liao J, Liu B, et al. Specific inhibition of Stat3 signal transduction by PIAS3. *Science*. 1997;278:1803-1805.
 21. Levy C, Nechushtan H, Razin E. A new role for the STAT3 inhibitor, PIAS3: a repressor of microphthalmia transcription factor. *J Biol Chem*. 2002;277:1962-1966.
 22. Levy C, Sonnenblick A, Razin E. The role played by MITF phosphorylation and its Zip domain in its transcriptional inhibition by PIAS3. *Mol Cell Biol*. 2003;23:9073-9080.
 23. Sonnenblick A, Levy C, Razin E. Interplay between MITF, PIAS3, and STAT3 in mast cells and melanocytes. *Mol Cell Biol*. 2004;24:10584-10592.
 24. Miller AJ, Levy C, Davis IJ, Razin E, Fisher DE. Sumoylation of MITF and its related family members TFE3 and TFEB. *J Biol Chem*. 2005;280:146-155.
 25. Liu B, Gross M, ten Hoeve J, Shuai K. A transcriptional corepressor of Stat1 with an essential LXXLL signature motif. *Proc Natl Acad Sci U S A*. 2001;98:3203-3207.
 26. Jackson PK. A new RING for SUMO: wrestling transcriptional responses into nuclear bodies with PIAS family E3 SUMO ligases. *Genes Dev*. 2001;15:3053-3058.
 27. Duval D, Duval G, Kedinger C, Poch O, Boeuf H. The 'PINIT' motif, of a newly identified conserved domain of the PIAS protein family, is essential for nuclear retention of PIAS3L. *FEBS Lett*. 2003;554:111-118.
 28. Bryce PJ, Miller ML, Miyajima I, Tsai M, Galli SJ, Oettgen HC. Immune sensitization in the skin is enhanced by antigen-independent effects of IgE. *Immunity*. 2004;20:381-392.
 29. Krieg PA, Melton DA. In vitro RNA synthesis with SP6 RNA polymerase. *Methods Enzymol*. 1987;155:397-415.
 30. Frangioni JV, Neel BG. Solubilization and purification of enzymatically active glutathione S-transferase (pGEX) fusion proteins. *Anal Biochem*. 1993;210:179-187.
 31. Besser D, Bromberg JF, Darnell JE Jr, Hanafusa H. A single amino acid substitution in the v-Eyk intracellular domain results in activation of Stat3 and enhances cellular transformation. *Mol Cell Biol*. 1999;19:1401-1409.
 32. Goldstein RE, Jimenez G, Cook O, Gur D, Paroush Z. Hucklebein repressor activity in *Drosophila* terminal patterning is mediated by Groucho. *Development*. 1999;126:3747-3755.
 33. McGuffin LJ, Bryson K, Jones DT. The PSIPRED protein structure prediction server. *Bioinformatics*. 2000;16:404-405.
 34. Kim DE, Chivian D, Baker D. Protein structure prediction and analysis using the Robetta server. *Nucleic Acids Res*. 2004;32:W526-W531.
 35. Rohl CA, Strauss CE, Misura KM, Baker D. Protein structure prediction using Rosetta. *Methods Enzymol*. 2004;383:66-93.
 36. Benson DA, Karsch-Mizrachi I, Lipman DJ, Ostell J, Wheeler DL. GenBank. *Nucleic Acids Res*. 2005;33:D34-D38.
 37. Thompson JD, Higgins DG, Gibson TJ. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. *Nucleic Acids Res*. 1994;22:4673-4680.
 38. Kamaraju AK, Bertolotto C, Chebath J, Revel M. Pax3 down-regulation and shut-off of melanogenesis in melanoma B16/F10.9 by interleukin-6 receptor signaling. *J Biol Chem*. 2002;277:15132-15141.
 39. Carreira S, Liu B, Goding CR. The gene encoding the T-box factor Tbx2 is a target for the microphthalmia-associated transcription factor in melanocytes. *J Biol Chem*. 2000;275:21920-21927.
 40. Ito A, Morii E, Kim D-K, et al. Inhibitory effect of the transcription factor encoded by the mi mutant allele in cultured mast cells of mice. *Blood*. 1999;93:1189-1196.
 41. Niu G, Wright KL, Huang M, et al. Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. *Oncogene*. 2002;21:2000-2008.
 42. Joo A, Aburatani H, Morii E, Iba H, Yoshimura A. STAT3 and MITF cooperatively induce cellular transformation through upregulation of c-fos expression. *Oncogene*. 2004;23:726-734.
 43. Kuhn M, Meiler J, Baker D. Strand-loop-strand motifs: prediction of hairpins and diverging turns in proteins. *Proteins*. 2004;54:282-288.
 44. Creighton TE. *Proteins: Structures and Molecular Properties*, 1st ed. WH Freeman; New York, 1992:512.
 45. Jang HD, Yoon K, Shin YJ, Kim J, Lee SY. PIAS3 suppresses NF-kappaB-mediated transcription by interacting with the p65/RelA subunit. *J Biol Chem*. 2004;279:24873-24880.
 46. Sentis S, Le Romancer M, Bianchin C, Rostan MC, Corbo L. Sumoylation of the estrogen receptor alpha hinge region regulates its transcriptional activity. *Mol Endocrinol*. 2005;19:2671-2684.
 47. Miller AJ, Levy C, Davis IJ, Razin E, Fisher DE. Sumoylation of MITF and its related family members TFE3 and TFEB. *J Biol Chem*. 2005;280:146-155.